Bradley Willcox Joins Cardax Pharmaceuticals Inc. Scientific Advisory Board
June 27, 2011 - Honolulu, HI: Cardax Pharmaceuticals, a Honolulu-based biotech technology company specializing in drugs that treat inflammation driven by oxidative stress, announced today that Bradley J. Willcox M.D. MSc, CAQ Geriatrics, has joined its Scientific Advisory Board (SAB).
An internationally known expert in healthy aging, Dr. Bradley J. Willcox is a Clinical Associate Professor in Geriatric Medicine at the University of Hawaii and a U.S. National Institutes of Health-funded scientist who conducts groundbreaking research on mechanisms of aging. He is Principal Investigator of the Kuakini Hawaii Lifespan Study, co-Principal Investigator of the Okinawa Centenarian Study, and co-investigator of the National Cancer Institute’s PLCO Study. These studies are among the largest ongoing studies of aging, cancer and longevity in the world. He trained in Medicine at the University of Toronto, Internal Medicine at the Mayo Clinic and Geriatric Medicine at Harvard Medical School. Dr. Willcox has published over 50 peer-reviewed papers in prestigious journals such as Proceedings of the National Academy of Sciences, the New England Journal of Medicine and JAMA and recently led a team that found a novel gene had major effects on our ability to live a long and healthy life.
“I am delighted to become an advisor to Cardax on clinical and scientific strategy,” said Dr. Willcox. “I believe treating inflammation is key to healthy aging because of its contributory role to many chronic diseases of old age and possibly to aging itself. Cardax is on the cusp of developing therapeutics with tremendous possibilities to treat aging related diseases, particularly where inflammation and oxidative stress are implicated.”
“Brad Willcox brings years of innovative geriatrics research and clinical experience to our team,” said David G. Watumull, President and CEO of Cardax Pharmaceuticals. “His guidance will be extraordinarily beneficial to our Scientific Advisory Board.”
“Dr. Willcox’s appointment to our SAB exemplifies our commitment to focus on the development of therapies that address the underlying causes for chronic diseases common to aging rather than the customary organ-by-organ piecemeal approach,” added Fredric J. Pashkow, M.D., Cardax Chief Medical Officer.
About Cardax Pharmaceuticals: Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. The Company’s platform includes CDX-085 with application in metabolic syndrome, arthritis, and cardiovascular disease, as well as other proprietary prodrugs for macular degeneration and prostate disease.
Contact: Cardax Pharmaceuticals, Inc.
David G. Watumull, 808 457-1375 or,
Fredric J. Pashkow, 808 457-1391
2800 Woodlawn Dr.
Honolulu, HI 96822
Released June 27, 2011